-+ 0.00%
-+ 0.00%
-+ 0.00%

TME Pharma, TMS Sign Agreements for Oncology Asset

MT Newswires·10/29/2026 07:43:56
Listen to the news
07:43 AM EDT, 10/29/2026 (MT Newswires) -- TME Pharma (ALTME.PA) signed a deal for the proposed development and commercialization of its glioblastoma drug NOX-A12, or olaptesed pegol, with Japan's TMS Co. Specifically, the European biotech company signed a 150,000-euro six-month exclusive negotiation agreement with TMS as part of strategic options for its leading oncology asset, according to a Thursday filing. The two parties also agreed to a nonbinding term sheet for exclusive access to NOX-A12 in which TME Pharma could receive 10 million euros in upfront and near-term payments and 100 million euros in regulatory and commercial sales milestones, among others.